Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: Consequences for FK506 assimilation

Kidney International

Volumn 67, Issue 3, 2005, Pages 1152-1160

  Lemahieu, Wim P D ^a   Maes, Bart D ^a   Verbeke, Kristin ^a   Vanrenterghem, Yves ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

CYP3A4; Gastric acid suppressants; Tacrolimus; Transplantation

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; ACETYLSALICYLIC ACID; ALLOPURINOL; ALPRAZOLAM; AMINOPHENAZONE; AMIODARONE; AMLODIPINE; ATENOLOL; ATORVASTATIN; BISOPROLOL; CARBAMAZEPINE; CHLORAZEPAM; CIMETIDINE; CLONAZEPAM; CLOPIDOGREL; CYTOCHROME P450 3A4; DIGOXIN; ENALAPRIL; ERYTHROMYCIN; GLIQUIDONE; GLYCOPROTEIN P; INSULIN; LISINOPRIL; LOSARTAN; MOLSIDOMINE; OMEPRAZOLE; RANITIDINE; TACROLIMUS; UNINDEXED DRUG; VITAMIN B COMPLEX; ANTIULCER AGENT; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450;

ADULT; AGED; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME METABOLISM; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; STOMACH ACID SECRETION; ULCER; URINALYSIS; COHORT ANALYSIS; DRUG INTERACTION; METABOLISM; MIDDLE AGED; SECRETION; STOMACH ACID;

ADULT; AGED; ANTI-ULCER AGENTS; CIMETIDINE; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; GASTRIC ACID; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OMEPRAZOLE; P-GLYCOPROTEIN; TACROLIMUS;

EID: 20844434515     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00182.x     Document Type: Article

References (37)

1. WATKINS PB: Drug metabolism by cytochromes P450 in the liver and small bowel. Gastrointestinal Pharmacol 23:511-525, 1992
2. LO A, BURCKART GJ: P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 39:995-1005, 1999
3. DE WILDT SN, KEARNS GL, LEEDER JS, VAN DEN ANKER JN: Cytochrome P450 3A. Ontogeny and drug disposition. Clin Pharmacokinet 37:485-505, 1999
4. SEIFELDIN R: Drug interactions in transplantation. Clin Ther 17:1043-1061, 1995
5. CHRISTIANS U, JACOBSEN W, BENET LZ, LAMPEN A: Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41:813-851, 2002
6. VAN ROERMUND HP, TIGGELER RG, BERDEN JH, et al: Cimetidine prophylaxis after renal transplantation. Clin Nephrol 18:39-42, 1982
7. WALTER S, THORUP ANDERSEN J, CHRISTENSEN U, et al: Effect of cimetidine on upper gastrointestinal bleeding after renal transplantation: a prospective study. BMJ 289:1175-1176, 1984
8. SKALA I, MARECKOVA O, VITKO S, et al: Prophylaxis of acute gastroduodenal bleeding after renal transplantation. Transpl Int 10:375-378, 1997
9. FURUTA S, KAMADA E, SUZUKI T, et al: Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidin and omeprazole. Xenobiotica 31:1-10, 2001
10. SZUTOWSKI MM, LUKASIK M, WAWER ZT, et al: In vivo effect of 5- and 8-methoxypsoralens and cimetidin on R,S-warfarin metabolism in rat. J Appl Toxicol 22:327-332, 2002
11. LINDELL M, KARLSSON O, LENNERNAS H, et al: Variable expression of CYP and PGP genes in the human small intestine. Eur J Clin Invest 33:493-499, 2003
12. RENDIC S, RUF HH, WEBER P, KAJFEZ F: Cimetidine and ranitidine: Their interaction with human and pig liver microsomes and with purified cylochromeP-450. Eur J Drug Metab Pharmacokinet 9:195-200, 1984
13. MION F, QUENEAU PE, ROUSSEAU M, et al: Aminopyrine breath test: Development of a 13C-breath test for quantitative assessment of liver function in humans. Hepato-Gastroenterology 42:931-938, 1995
14. LEMAHIEU W, MAES B, VANRENTERGHEM Y, et al: Measurement of hepatic and intestinal cyp 3A4 and P-glycoprotein activity by means of a combined po and iv C14 erythromycin breath and urine test. Am J Physiol Gastrointest Liver Physiol 285:470-482, 2003
15. BOSWELL GW, BEKERSKY I, FAY J, et al: Tacrolimus pharmacokinetics in BMT patients. Bone Marrow Transplant 21:23-28, 1998
16. GHOOS YF, MAES B, GEYPENS BJ, et al: Measurement of gastric emptying rate of solids by means of a carbon labbelled octanoic breath test. Gastroenterology 104:1640-1647, 1993
17. EVENEPOEL P, HIELE M, LUYPAERTS A, et al: Production of egg proteins, enriched with L-leucine-13C1, for the study of protein assimilation in humans using the breath test technique. J Nutr 127:327-331, 1997
18. MAES BD, MYS G, GEYPENS BJ, et al: Gastric emptying flow curves separated from carbon-labeled octanoic acid breath test results. Am J Physiol Gastrointest Liver Physiol 275:169-175, 1998
19. IRVING CS, SCHOELLER DA, NAKAMURA KI, et al: The aminopyrin breath test as a measure of liver function. J Lab Clin Med 100:3563-3573, 1982
20. PLOSKER GL, FOSTER RH: Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 59:323-389, 2000
21. UNDRE NA, SCHÄFER A: European Tacrolimus Multicentre Renal Study Group. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. Transplant Proc 30:1261-1263, 1998
22. SHIMADA T, TERADA AI, YOKOGAWA K, et al: Lowered blood concentration of tacrolimus and its recovery with changes in expression of cyp3A and P-glycoprotein after high-dose steroid therapy. Transplantation 74:1419-1424, 2002
23. ANDREEV E, KOOPMAN M, ARISZ L: A rise in plasma creatinine that is not a sign of renal failure: Which drugs can be responsible? J Intern Med 246:247-252, 1999
24. NIWA T, SATO R, YABUSAKI Y, et al: Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica 29:187-193, 1999
25. PARKER AC, PRITCHARD P, PRESTON T, et al: Lack of inhibitory effect of cimetidine on caffeine metabolism in children using the caffeine breath test. Br J Clin Pharmacol 43:467-470, 1997
26. Loi CM, PARKER BM, CUSACK BJ, et al: Aging and drug interactions. III. Individual and combined effects of cimetidin and cimetidin and ciprofloxacin on theophyllin metabolism in healthy male and female nonsmokers. J Pharmacol Exp Ther 280:627-637, 1997
27. MOJTAHEDZADEH M, SADRAY S, HADJIBABAIE M, et al: Determination of theophyllin clearance after cimetidin infusion in critically ill patients. J Infus Nurs 26:234-238, 2003
28. O'REILLY RA: Comparative interaction of cimetidin and ranitidin with racemic warfarin in man. Arch Intern Med 144:989-991, 1984
29. HEAGERTY AM, DONOVAN MA, CASTLEDEN CM, et al: Influence of cimetidin on pharmacokinetics of propranolol. BMJ 13:1917-1919, 1981
30. CURI-PEDROSA R, DAUJAT M, PICHARD L, et al: Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 269:384-392, 1994
31. RAUCY JL: Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 31:533-539, 2003
32. REICHENSPURNER H, MEISER BM, MUSCHIOL F, et al: Changes of reSorption and metabolism of cyclosporine after heart transplantation by the influence of gastrointestinal agents. Transplant Proc 26:2800-2801, 1994
33. SHAEFER MS, ROSSI SJ, MCGUIRE TR, et al: Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. Ann Pharmacother 29:1088-1091, 1995
34. PUFF MR, CAREY WD: The effect of cimetidine on cyclosporine A levels in liver transplant recipients: A preliminary report. Am J Gastroenterol 87:287-291, 1992
35. BARRI YM, RAMOS EL, BALAGTAS RS, et al: Cimetidine or ranitidine in renal transplant patients receiving cyclosporine. Clin Transplant 10:34-38, 1996
36. BLOHME I, IDSTROM JP, ANDERSSON T: A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Br J Clin Pharmacol 35:156-160, 1993
37. LEMAHIEU WP, MAES BD, VERBEKE K, et al: CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporine vs. tacrolimus vs. sirolimus. Am J Tranplant 4:1514-1522, 2004